Mortality rates increased for Medicare beneficiaries with cardiovascular disease or risk factors during the later stages of the COVID-19 pandemic, even as hospitalizations for this group decreased, according to a recent analysis by Medscape Medical News.
The findings suggest a complex interplay between the pandemic’s progression and health outcomes for a vulnerable population. While fewer individuals with heart conditions required hospitalization, those who ultimately succumbed to illness experienced a higher mortality rate compared to pre-pandemic periods. This shift raises questions about potential changes in access to care, the severity of circulating viral strains, and the overall impact of pandemic-related disruptions on cardiovascular health management.
Researchers examining Medicare data noted the trend emerged as the pandemic evolved, indicating a possible alteration in the patterns of illness and death among beneficiaries. The American Journal of Managed Care® has also reported on the impact of the COVID-19 pandemic on care quality metrics within Medicare, highlighting broader challenges in maintaining consistent healthcare delivery during the crisis.
The observed increase in mortality coincides with a period where healthcare systems were grappling with surges in COVID-19 cases, staffing shortages, and limitations in resources. These factors may have contributed to delays in diagnosis, treatment, or preventative care for individuals with cardiovascular conditions. The KFF reports that Medicare provides coverage for COVID-19 testing and treatment, but access to care remained a significant issue throughout the pandemic.
A study by the American Hospital Association revealed that beneficiaries enrolled in Medicare Advantage (MA) plans experienced longer hospital stays compared to those with traditional Medicare. This disparity in length of stay could potentially influence mortality rates and resource utilization within the Medicare system. The reasons for these longer stays in MA plans are still being investigated, but may relate to differences in care coordination, network restrictions, or utilization management practices.
The Medscape analysis did not specify the exact timeframe defining the “later stages” of the pandemic, nor did it detail the specific cardiovascular conditions included in the study population. Further research is needed to fully understand the underlying mechanisms driving these observed trends and to identify targeted interventions to improve outcomes for Medicare beneficiaries with cardiovascular disease.
